



## **InfiniteVision Optics SAS Completes Series A Financing Round**

Strasbourg, 25 June 2015

InfiniteVision Optics (IVO), European's innovative company for adjustable intraocular lenses for cataract and refractive surgery, announces that it has raised capital funding of EUR 1.7 million. The capital increase was led by Cap Innov'Est, a regional investment fund managed by Alsace Capital in collaboration with Invest PME, and by Remora Capital, a Swiss-based investor in health & beauty innovation and IVO's historical partner. Existing shareholders including the founders completed the round.

Carsten Laue, IVO's CEO, said: "We are very pleased to have secured these funds which enable us to advance our clinical programs. The recent international cataract and refractive surgery events highlighted the continuous need of new options to achieve spectacle free vision after cataract surgery." He continued: "I am delighted that Cap Innov'Est and Remora Capital together with our historic private investors, have demonstrated their confidence in the company's technology, clinical programs and management team."

Jean-Francois Rax, from Alsace Capital comments: "We strongly believe that IVO has everything to be a successful company: a strong scientific and technical background, an experienced management team and a thoughtful product design."

Jean-Marc Le Doussal, President at Remora Capital says: "As historical seed investor in IVO, we have financed and developed the technology with Dr. Laue until the point where it can now be tested in clinical trials. We are proud to continue supporting the highly skilled IVO entrepreneurs."

The funds obtained will allow the company to advance its adjustable Precisight™ intraocular lens product through regulatory pathway towards CE marking and commercialization phase.



### **About Infinite Vision Optics SAS**

Founded in 2010, Infinite Vision Optics (IVO) has developed the Precisight™ intraocular lens system that allows the adjustment of the IVO intraocular lens throughout the patient's life when needed. A full lens explantation is replaced by a simple and minimally invasive secondary procedure. This proprietary *docking station* system provides surgeons a solution to achieve the best possible refractive outcome by substantially reducing the risk associated with full lens explantation as well as providing the patient with solutions to refractive and medical changes throughout their lifetime that cannot be predicted at the time of the initial cataract procedure. The company is based in Strasbourg, France and has received the label "Entreprise Innovante des Pôles" in 2012.

### **About Cap Innov'Est**

Cap Innov'Est is a 36M€ tri-regional (Alsace, Bourgogne, Franche-Comté) fund dedicated to investments in young innovative start-ups. Cap Innov'Est was launched in July 2014 and has already invested in 6 start-ups. Cap Innov'Est is supported by Fonds National d'Amorçage, the 3 Regions Alsace, Bourgogne et Franche-Comté, SAFIDI, caisses d'épargne d'Alsace et Bourgogne/Franche-Comté, BNP Paribas et CIFIC. For more information: [www.alsacecapital.eu](http://www.alsacecapital.eu)

### **About Remora Capital SA**

Remora Capital SA, Lausanne, Switzerland, is an independent entrepreneurial investment company specialized in the healthcare and beauty care innovation. Leveraging on its entrepreneurial, industrial and scientific expertise, Remora Capital provides hands-on, sustainable and value-creative support to innovative companies in Switzerland and surrounding countries.

### **Contact:**

Infinite Vision Optics SAS  
4, rue Boussingault  
F-67000 Strasbourg  
[www.infinitevisionoptics.com](http://www.infinitevisionoptics.com)

Remora Partners SA  
rue du Petit Chêne 12  
CH-1003 Lausanne  
[www.remora-partners.ch](http://www.remora-partners.ch)